Activin type IB receptor signaling in prostate cancer cells promotes lymph node metastasis in a xenograft model

Biochemical and Biophysical Research Communications

Volumn 430, Issue 1, 2013, Pages 340-346

  Nomura, Masatoshi ^a   Tanaka, Kimitaka ^a   Wang, Lixiang ^a   Goto, Yutaka ^a   Mukasa, Chizu ^a   Ashida, Kenji ^a   Takayanagi, Ryoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Activin type IB receptor; Epithelial mesenchymal transition; Lymph node; Metastasis; Prostate cancer cells; S100A4; Snail

Indexed keywords

ACTIVIN RECEPTOR 1; ACTIVIN RECEPTOR 1B; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

GASTROPODA; MUS;

EID: 84872418296     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.11.011     Document Type: Article

References (27)

1. Denis L.J., Griffiths K. Endocrine treatment in prostate cancer. Semin. Surg. Oncol. 2000, 18:52-74.
2. G. Crehange, C.P. Chen, C.C. Hsu, et al., Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm, Cancer Treat. Rev., 2012 (epub ahead of print).
3. Blobe G.C., Schiemann W.P., Lodish H.F. Role of transforming growth factor beta in human disease. N. Engl. J. Med. 2000, 342:1350-1358.
4. Massague J. TGF beta in cancer. Cell 2008, 134:215-230.
5. Roberts A.B., Wakefield L.M. The two faces of transforming growth factor β in carcinogenesis. Proc. Natl. Acad. Sci. 2003, 100:8621-8623.
6. Ikushima H., Miyazono K. TGFβ signalling: a complex web in cancer progression. Nat. Rev. Cancer 2008, 10:415-424.
7. Barrack E.R. TGF-β in prostate cancer: a growth inhibitor that can enhance tumorigenicity. The Prostate 1997, 31:61-70.
8. Wikstrom P., Stattin P., Franck-Lissbrant I., et al. Transforming growth factor b1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998, 37:19-29.
9. Massague J., Chen Y.G. Controlling TGF-β signaling. Genes Dev. 2000, 14:627-644.
10. Wang Q.F., Tilly K.I., Tilly J.L., et al. Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line. LNCaP Endocrinol. 1996, 137:5476-5483.
11. Ball E.M., Risbridger G.P. Activins as regulators of branching morphogenesis. Dev. Biol. 2001, 238:1-12.
12. Willis S.A., Zimmerman C.M., Li L.I., Mathews L.S. Formation and activation by phosphorylation of activin receptor complexes. Mol. Endocrinol. 1996, 10:367-379.
13. Lebrun J.J., Takabe K., Chen Y., Vale W. Roles of pathway-specific and inhibitory Smads in activin receptor signaling. Mol. Endocrinol. 1999, 13:15-23.
14. Nakhla A.M., Rosner W. Characterization of ALVA-41 cells, a new human prostatic cnacer cell line. Steroids 1994, 59:586-589.
15. Gieni R.S., Li Y., HayGlass K.T. Comparison of [3H] thymidine incorporation with MTT- and MTS-based bioassays for human and murine IL-2 and IL-4 analysis. Tetrazollium assays provide markedly enhanced senseitivity. J. Imunol. Method. 1995, 187:85-93.
16. Mukasa C., Nomura M., Tanaka T., Tanaka K., et al. Activin signaling through type IB activin receptor stimulates aromatase activity in the ovarian granulose cell-like human granulose (KGN) cells. Endocrinology 2003, 144:1603-1611.
17. Risridger G.P., Mellor S.L., McPherson S.J., Schmitt J.F. The contribution of inhibins and activins to malignant prostate diseases. Mol. Cell Endocrinol. 2001, 180:149-153.
18. Kang H.-Y., Huang H.-Y., Hsieh C.-Y., Li C.-F., et al. Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer. J. Bone Miner. Res. 2009, 24:1180-1193.
19. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of developmnet and tumor metastasis. Dev. Cell 2008, 14:818-829.
20. Peinado H., Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat. Rev. Cancer 2007, 7:415-428.
21. Yoshinaga K., Mimori K., Yamashita K., et al. Clinical significance of the expression of activin A in esophageal carcinoma. Int. J. Oncol. 2003, 22:75-80.
22. Ferreira M.C., Witz C.A., Hammes L.S., et al. Activin A increases invasiveness of endometrial cells in an in vitro model of human peritoneum. Mol. Hum. Reproduc. 2008, 14:301-307.
23. Garrett S.C., Varney K.M., Weber D.J., et al. S100A4, a mediator of metastasis. J. Biol. Chem. 2006, 281:677-680.
24. Matsuura I., Lai C.Y., Chiang K.-N. Functional interaction between Smad3 and S100A4 (metastatin-1) for TGF-β-medicated cancer cell invasiveness. Biochem. J. 2010, 426:327-335.
25. Martin O., Rosemary J.A., Allan B. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat. Cell Biol. 2002, 4:487-496.
26. Reinholz M.M., Iturria S.J., Ingle J.N., Roche P.C. Differntial gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR. Breast Cancer Res. Treat. 2002, 74:255-269.
27. Vo B.T., Khan S.A. Expression of nodal and nodal receptors in prostate stem cells and prostate cancer cells: autocrine effects on cell proliferation and migration. Prostate 2011, 71:1084-1096.